APO Research
Talk to an analyst

APO RESEARCH · REPORT

Imatinib Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Imatinib Drugs Market Outlook and Growth Opportunities 2026

22 December 2025193 pages

Choose your research edition.

Industry ResearchImatinib Drugs Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Imatinib Drugs Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Imatinib Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Imatinib Drugs Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Imatinib Drugs Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Imatinib Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Imatinib Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Imatinib Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Imatinib Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Imatinib Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Imatinib Drugs market include Teva, Sun Pharmaceuticals, Sanofi S.A., Novartis, Glenmark Pharmaceuticals Ltd., Viatris, Dr. Reddy's Laboratories, Cipla Inc. and Apotex Inc., among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Imatinib Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Imatinib Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Imatinib Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Imatinib Drugs market.

Imatinib Drugs Segment by Company

Teva

Sun Pharmaceuticals

Sanofi S.A.

Novartis

Glenmark Pharmaceuticals Ltd.

Viatris

Dr. Reddy's Laboratories

Cipla Inc.

Apotex Inc.

Imatinib Drugs Segment by Type

Capsules

Tablets

Imatinib Drugs Segment by Application

Hospitals

Drug Stores

Others

Imatinib Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Imatinib Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Imatinib Drugs key companies, revenue, market share, and recent developments.

3. To split the Imatinib Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Imatinib Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Imatinib Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Imatinib Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Imatinib Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Imatinib Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Imatinib Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Imatinib Drugs industry.

Chapter 3: Detailed analysis of Imatinib Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Imatinib Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Imatinib Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Imatinib Drugs Industry Trends Table 2. Imatinib Drugs Industry Drivers Table 3. Imatinib Drugs Industry Opportunities and Challenges Table 4. Imatinib Drugs Industry Restraints Table 5. Global Imatinib Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Imatinib Drugs Revenue Share by Company (2021-2026) Table 7. Global Imatinib Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Imatinib Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Imatinib Drugs Company, Product Type & Application Table 10. Global Imatinib Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Imatinib Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Capsules Table 15. Significant Companies of Tablets Table 16. Global Imatinib Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Imatinib Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Imatinib Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Imatinib Drugs Sales Value Share by Type (2021-2026) Table 20. Global Imatinib Drugs Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospitals Table 22. Significant Companies of Drug Stores Table 23. Significant Companies of Others Table 24. Global Imatinib Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Imatinib Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Imatinib Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Imatinib Drugs Sales Value Share by Application (2021-2026) Table 28. Global Imatinib Drugs Sales Value Share by Application (2027-2032) Table 29. Global Imatinib Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Imatinib Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Imatinib Drugs Sales Value Share by Region (2021-2026) Table 32. Global Imatinib Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Imatinib Drugs Sales Value Share by Region (2027-2032) Table 34. Global Imatinib Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Imatinib Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Imatinib Drugs Sales Value Market Share by Country (2021-2026) Table 37. Global Imatinib Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Imatinib Drugs Sales Value Market Share by Country (2027-2032) Table 39. Teva Company Information Table 40. Teva Business Overview Table 41. Teva Imatinib Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Teva Imatinib Drugs Product Portfolio Table 43. Teva Recent Development Table 44. Sun Pharmaceuticals Company Information Table 45. Sun Pharmaceuticals Business Overview Table 46. Sun Pharmaceuticals Imatinib Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Sun Pharmaceuticals Imatinib Drugs Product Portfolio Table 48. Sun Pharmaceuticals Recent Development Table 49. Sanofi S.A. Company Information Table 50. Sanofi S.A. Business Overview Table 51. Sanofi S.A. Imatinib Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Sanofi S.A. Imatinib Drugs Product Portfolio Table 53. Sanofi S.A. Recent Development Table 54. Novartis Company Information Table 55. Novartis Business Overview Table 56. Novartis Imatinib Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Novartis Imatinib Drugs Product Portfolio Table 58. Novartis Recent Development Table 59. Glenmark Pharmaceuticals Ltd. Company Information Table 60. Glenmark Pharmaceuticals Ltd. Business Overview Table 61. Glenmark Pharmaceuticals Ltd. Imatinib Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Glenmark Pharmaceuticals Ltd. Imatinib Drugs Product Portfolio Table 63. Glenmark Pharmaceuticals Ltd. Recent Development Table 64. Viatris Company Information Table 65. Viatris Business Overview Table 66. Viatris Imatinib Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Viatris Imatinib Drugs Product Portfolio Table 68. Viatris Recent Development Table 69. Dr. Reddy's Laboratories Company Information Table 70. Dr. Reddy's Laboratories Business Overview Table 71. Dr. Reddy's Laboratories Imatinib Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Dr. Reddy's Laboratories Imatinib Drugs Product Portfolio Table 73. Dr. Reddy's Laboratories Recent Development Table 74. Cipla Inc. Company Information Table 75. Cipla Inc. Business Overview Table 76. Cipla Inc. Imatinib Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Cipla Inc. Imatinib Drugs Product Portfolio Table 78. Cipla Inc. Recent Development Table 79. Apotex Inc. Company Information Table 80. Apotex Inc. Business Overview Table 81. Apotex Inc. Imatinib Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Apotex Inc. Imatinib Drugs Product Portfolio Table 83. Apotex Inc. Recent Development Table 84. Research Programs/Design for This Report Table 85. Authors List of This Report Table 86. Secondary Sources Table 87. Primary Sources List of Figures Figure 1. Imatinib Drugs Product Image Figure 2. Global Imatinib Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Imatinib Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Imatinib Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Capsules Image Figure 8. Tablets Image Figure 9. Global Imatinib Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Imatinib Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Imatinib Drugs Sales Value Share by Type (2021-2032) Figure 12. Hospitals Image Figure 13. Drug Stores Image Figure 14. Others Image Figure 15. Global Imatinib Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Imatinib Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Imatinib Drugs Sales Value Share by Application (2021-2032) Figure 18. Global Imatinib Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Imatinib Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Imatinib Drugs Sales Value (2021-2032) & (US$ Million) Figure 21. North America Imatinib Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Imatinib Drugs Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Imatinib Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Imatinib Drugs Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Imatinib Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Imatinib Drugs Sales Value (2021-2032) & (US$ Million) Figure 27. South America Imatinib Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Imatinib Drugs Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Imatinib Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Imatinib Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Imatinib Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Imatinib Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Imatinib Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Imatinib Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Imatinib Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Imatinib Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Imatinib Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Imatinib Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Imatinib Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Imatinib Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Imatinib Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Imatinib Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Imatinib Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Imatinib Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Imatinib Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Imatinib Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Imatinib Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Imatinib Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Imatinib Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Imatinib Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Imatinib Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Imatinib Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Imatinib Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Imatinib Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Imatinib Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Imatinib Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Imatinib Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Imatinib Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Imatinib Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Imatinib Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Imatinib Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Imatinib Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Imatinib Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Imatinib Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Imatinib Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Imatinib Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Imatinib Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Imatinib Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Imatinib Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Imatinib Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Imatinib Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Imatinib Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Imatinib Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Imatinib Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Imatinib Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Imatinib Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Imatinib Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Imatinib Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Imatinib Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Imatinib Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Imatinib Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Imatinib Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Imatinib Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Imatinib Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Imatinib Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Imatinib Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Imatinib Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Imatinib Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Imatinib Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Imatinib Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Imatinib Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Imatinib Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Imatinib Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Imatinib Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Imatinib Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Imatinib Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Imatinib Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Imatinib Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Imatinib Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Imatinib Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Imatinib Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Imatinib Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Imatinib Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Imatinib Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Imatinib Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Imatinib Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Imatinib Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Imatinib Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Imatinib Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Imatinib Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Imatinib Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Imatinib Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Imatinib Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Capsules
  • Tablets
Applications
  • Hospitals
  • Drug Stores
  • Others
Companies covered
  • Teva
  • Sun Pharmaceuticals
  • Sanofi S.A.
  • Novartis
  • Glenmark Pharmaceuticals Ltd.
  • Viatris
  • Dr. Reddy's Laboratories
  • Cipla Inc.
  • Apotex Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Imatinib Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Imatinib Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Imatinib Drugs Market Dynamics
  1. 2.1 Imatinib Drugs Industry Trends
  2. 2.2 Imatinib Drugs Industry Drivers
  3. 2.3 Imatinib Drugs Industry Opportunities and Challenges
  4. 2.4 Imatinib Drugs Industry Restraints
3 Imatinib Drugs Market by Company
  1. 3.1 Global Imatinib Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Imatinib Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Imatinib Drugs Company Ranking (2024-2026)
  4. 3.4 Global Imatinib Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Imatinib Drugs Company Product Type and Application
  6. 3.6 Global Imatinib Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Imatinib Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Imatinib Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Imatinib Drugs Market by Type
  1. 4.1 Imatinib Drugs Type Introduction
  2. 4.1.1 Capsules
  3. 4.1.2 Tablets
  4. 4.2 Global Imatinib Drugs Sales Value by Type
  5. 4.2.1 Global Imatinib Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Imatinib Drugs Sales Value by Type (2021-2032)
  7. 4.2.3 Global Imatinib Drugs Sales Value Share by Type (2021-2032)
5 Imatinib Drugs Market by Application
  1. 5.1 Imatinib Drugs Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Drug Stores
  4. 5.1.3 Others
  5. 5.2 Global Imatinib Drugs Sales Value by Application
  6. 5.2.1 Global Imatinib Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Imatinib Drugs Sales Value by Application (2021-2032)
  8. 5.2.3 Global Imatinib Drugs Sales Value Share by Application (2021-2032)
6 Imatinib Drugs Regional Value Analysis
  1. 6.1 Global Imatinib Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Imatinib Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Imatinib Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Imatinib Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Imatinib Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Imatinib Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Imatinib Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Imatinib Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Imatinib Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Imatinib Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Imatinib Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Imatinib Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Imatinib Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Imatinib Drugs Sales Value Share by Country, 2025 VS 2032
7 Imatinib Drugs Country-level Value Analysis
  1. 7.1 Global Imatinib Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Imatinib Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Imatinib Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Imatinib Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Imatinib Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Imatinib Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Imatinib Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Imatinib Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Imatinib Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Imatinib Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Imatinib Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Imatinib Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Imatinib Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Imatinib Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Imatinib Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Imatinib Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Imatinib Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Imatinib Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Imatinib Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Imatinib Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Imatinib Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Imatinib Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Imatinib Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Imatinib Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Imatinib Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Imatinib Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Imatinib Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Imatinib Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Imatinib Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Imatinib Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Imatinib Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Imatinib Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Imatinib Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Imatinib Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Imatinib Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Imatinib Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Imatinib Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Imatinib Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Imatinib Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Imatinib Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Imatinib Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Imatinib Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Imatinib Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Imatinib Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Imatinib Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Imatinib Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Imatinib Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Imatinib Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Imatinib Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Imatinib Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Imatinib Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Imatinib Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Imatinib Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Imatinib Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Imatinib Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Imatinib Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Imatinib Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Imatinib Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Imatinib Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Imatinib Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Imatinib Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Imatinib Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Imatinib Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Imatinib Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Imatinib Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Imatinib Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Imatinib Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Imatinib Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Imatinib Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Imatinib Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Imatinib Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Imatinib Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Imatinib Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Imatinib Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Imatinib Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Imatinib Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Imatinib Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Imatinib Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Imatinib Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Imatinib Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Imatinib Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Imatinib Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Imatinib Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Imatinib Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Imatinib Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Imatinib Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Imatinib Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Imatinib Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva Imatinib Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Imatinib Drugs Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Sun Pharmaceuticals
  8. 8.2.1 Sun Pharmaceuticals Company Information
  9. 8.2.2 Sun Pharmaceuticals Business Overview
  10. 8.2.3 Sun Pharmaceuticals Imatinib Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sun Pharmaceuticals Imatinib Drugs Product Portfolio
  12. 8.2.5 Sun Pharmaceuticals Recent Developments
  13. 8.3 Sanofi S.A.
  14. 8.3.1 Sanofi S.A. Company Information
  15. 8.3.2 Sanofi S.A. Business Overview
  16. 8.3.3 Sanofi S.A. Imatinib Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi S.A. Imatinib Drugs Product Portfolio
  18. 8.3.5 Sanofi S.A. Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Imatinib Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Imatinib Drugs Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Glenmark Pharmaceuticals Ltd.
  26. 8.5.1 Glenmark Pharmaceuticals Ltd. Company Information
  27. 8.5.2 Glenmark Pharmaceuticals Ltd. Business Overview
  28. 8.5.3 Glenmark Pharmaceuticals Ltd. Imatinib Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Glenmark Pharmaceuticals Ltd. Imatinib Drugs Product Portfolio
  30. 8.5.5 Glenmark Pharmaceuticals Ltd. Recent Developments
  31. 8.6 Viatris
  32. 8.6.1 Viatris Company Information
  33. 8.6.2 Viatris Business Overview
  34. 8.6.3 Viatris Imatinib Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Viatris Imatinib Drugs Product Portfolio
  36. 8.6.5 Viatris Recent Developments
  37. 8.7 Dr. Reddy's Laboratories
  38. 8.7.1 Dr. Reddy's Laboratories Company Information
  39. 8.7.2 Dr. Reddy's Laboratories Business Overview
  40. 8.7.3 Dr. Reddy's Laboratories Imatinib Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Dr. Reddy's Laboratories Imatinib Drugs Product Portfolio
  42. 8.7.5 Dr. Reddy's Laboratories Recent Developments
  43. 8.8 Cipla Inc.
  44. 8.8.1 Cipla Inc. Company Information
  45. 8.8.2 Cipla Inc. Business Overview
  46. 8.8.3 Cipla Inc. Imatinib Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Cipla Inc. Imatinib Drugs Product Portfolio
  48. 8.8.5 Cipla Inc. Recent Developments
  49. 8.9 Apotex Inc.
  50. 8.9.1 Apotex Inc. Company Information
  51. 8.9.2 Apotex Inc. Business Overview
  52. 8.9.3 Apotex Inc. Imatinib Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Apotex Inc. Imatinib Drugs Product Portfolio
  54. 8.9.5 Apotex Inc. Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst